Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31468348 | 0.79 | PARP1 (0.58) | PARP1KDM4ETP53NPC1RAB9A | |
| SCHEMBL15191719 | 0.78 | PARP1 (0.57) | PARP1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13534960 | 0.75 | PARP1 (0.51) | PARP1KDM4ENPC1RAB9AMEN1 | |
| SCHEMBL2336718 | 0.75 | KDM4E (0.51) | KDM4ETP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12326343 | 0.75 | FABP4 (0.50) | PARP1TP53MAPT | |
| SCHEMBL12291365 | 0.75 | PARP1 (0.53) | PARP1KDM4ETP53NPC1RAB9A | |
| SCHEMBL1278559 | 0.74 | KDM4E (0.41) | PARP1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL12291367 | 0.74 | LMNA (0.42) | PARP1TP53NPC1RAB9AMEN1 | |
| SCHEMBL1614054 | 0.73 | MEN1 (0.41) | KDM4ETP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20515291 | 0.72 | KDM4E (0.43) | KDM4ESMN1; SMN2MEN1KMT2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358716-B1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | MERCK SHARP & DOHME (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8815875-B2 | Inhibitors of fatty acid binding protein (FABP) | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815875-B2 | Inhibitors of fatty acid binding protein (FABP) | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110237575-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | MERCK SHARP & DOHME LLC | 2011-09-29 | — | — | US | disclosed |
| US-20110237575-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | MERCK SHARP & DOHME LLC | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237575-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | FABP4, FABP1, FABP3 | PARP1 3850/4885KDM4E 3104/4885TP53 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.